Todos 2022 accomplishments spoon fed 1 at a time. Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients January 27, 2022 8:23am EST https://investor.todosmedical.com/news-events/press-releases/detail/177/todos-medical-and-nlc-pharma-announce-primary-and-secondary
Market Data 
Markets 
